Recorded: March 11 2021

Venous Thromboembolism (VTE) occurs in up to 20% of patients with cancer and contributes significantly to morbidity and mortality up to 7-fold interfering with cancer treatment. Oncology patients have higher rates of VTE recurrence and of bleedings with anticoagulants and it can be the first clinical manifestation of an undiagnosed cancer. 

In light of the pandemic, patients have a cumulative higher risk for CAT, not only from cancer, but also from COVID-19 infection as well. Watch this webinar where we discuss the considerations, risks of thrombosis and the benefit of thromboprophylaxis in the COVID-19 era to avoid the negative clinical consequences and protect patients against the cumulative high risk for CAT.

Agenda:

• Cancer-Associated Thrombosis (CAT) and hemostatic disorders of COVID-19 disease in cancer patients – cumulative thrombosis risk with Dr Nikolaos Tsoukalas
• European data regarding thrombosis in cancer patients with COVID-19 disease with Dr. Carme Font
• Characterization of coagulopathy and related-outcomes in cancer patients with severe COVID-19 illness: Experience at a Comprehensive Cancer Center with Dr Cristhiam Rojas Hernandez
• Live Q&A moderated by Session Chair Dr Carmen Escalante